

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LILRB5/CD87c/LIR-8 in direct ELISA.
Source	Monoclonal Mouse IgG _{2B} Clone # 1058033
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line, NS0-derived human LILRB5/CD85c/LIR-8 Arg18-His456 Accession # O75023
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunocytochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1, 2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4) It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5). Consistent with the demonstrated binding of LILRB2 to Angiotensin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiotensin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.